(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial, showing a statistically significant but modest improvement in progression-free
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.